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Abstract: While clinical trials demonstrate the beneﬁ  ts of blood pressure and cholesterol 
reduction, medication adherence in clinical practice is problematic. We hypothesized that a 
single-pill would be superior to a 2-pill regimen for achieving adherence. In this retrospective, 
cohort study based on pharmacy claims data, patients newly initiated on a calcium channel 
blocker (CCB) or statin simultaneously or within 30 days, regardless of sequence, were followed 
(N = 4703). Adherence was measured over 6 months as proportion of days covered (PDC). At 
baseline, mean age was 63.0 years, 51.6% were female, and mean number of other medica-
tions was 7.8. Overall, 16.9% of patients were on single-pill amlodipine/atorvastatin, 15.6% 
amlodipine + atorvastatin, 24.7% amlodipine + other statin, 13.9% other CCB + atorvastatin, 
28.9% other CCB + other statin. Percentages of patients achieving adherence (PDC   80%) 
were: 67.7% amlodipine/atorva  statin; 49.9% amlodipine + atorvastatin; 40.4% amlodipine + 
other statin; 46.9% other CCB + atorvastatin; 37.4% other CCB + other statin. After adjusting 
for treatment selection and cohort differences, odds ratios for adherence with amlodipine/atorva-
statin were 1.95 (95% conﬁ  dence interval [CI], 1.80–2.13) vs amlodipine + atorvastatin, 3.10 
(95% CI, 2.85–3.38) vs amlodipine + other statin, 2.06 (95% CI, 1.89–2.24) vs other CCB + 
atorvastatin, 2.85 (95% CI, 2.61–3.10) vs other CCB + other statin (all p   0.0001). Single-pill 
amlodipine/atorvastatin may provide clinical beneﬁ  ts through improving adherence, offering 
clinicians a practical solution for cardiovascular risk management.
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Introduction
Recent clinical trials and meta-analyses have demonstrated the beneﬁ  ts of antihy-
pertensive and lipid-lowering therapies for the prevention of cardiovascular events 
(ALLHAT Ofﬁ  cers and Coordinators for the ALLHAT Collaborative Research Group 
2002; Sever et al 2003; Staessen et al 2003; Baigent et al 2005) and guidelines support 
an integrated approach to the reduction of cardiovascular risk (Expert Panel on Detec-
tion, Evaluation, and Treatment of High Blood Cholesterol in Adults 2001). However, 
few patients receive adequate antihypertensive and lipid-lowering treatment in clinical 
practice (Wong et al 2006). For example, only 9% of US adults with hypertension and 
dyslipidemia are at target levels for both blood pressure and low-density lipoprotein 
cholesterol (Wong et al 2006).
Among the key causes of this treatment gap may be poor patient adherence to 
cardiovascular medications (Wei et al 2002; Sokol et al 2005; Bramley et al 2006; 
Burnier 2006; Ho et al 2006; Kulkarni et al 2006). Several studies have observed that 
patient adherence to antihypertensive and/or lipid-lowering therapy is low (Benner et al 
2002; Blackburn et al 2005; Chapman et al 2005). The use of single-pill combination 
therapy may improve adherence by synchronizing therapies, so that medications are 
initiated at the same time (Chapman et al 2005; Agarwal et al 2008), and by reducing 
pill burden (Dezii 2000; Vanderpoel et al 2004; Chapman et al 2005; Gerbino and Vascular Health and Risk Management 2008:4(3) 674
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Shoheiber 2007) and out-of-pocket costs to the patient (Piette 
et al 2004; Soumerai et al 2006; Thiebaud et al 2008).
A single-pill therapy combining the antihypertensive 
medication, amlodipine besylate, and the 3-hydroxy-
3-methylglutaryl coenzyme A reductase inhibitor (statin), 
atorvastatin calcium, is the ﬁ  rst ﬁ  xed-dose combination 
therapy for the treatment of 2 major risk factors for cardio-
vascular disease (Blank et al 2005). This study sought to test 
the hypothesis that this single-pill therapy would be superior 
to a multi-pill antihypertensive and lipid-lowering treatment 
regimen in the achievement of adherence.
Methods
Study design
This adherence study was a retrospective, longitudinal, cohort 
study of a diverse, insured, nationally representative US 
population. Pharmacy claims were used to identify patients 
using calcium channel blocker (CCB) and statin therapy 
during the 16-month study period between April 1, 2004 
and July 30, 2005.
Data source
This study utilized national pharmacy administrative data 
from MedImpact Healthcare Systems, Inc. (San Diego, CA, 
USA) (Sullivan et al 2005; Thiebaud et al 2005, 2006, 2008; 
Patel et al 2007). MedImpact provides pharmacy beneﬁ  t 
management services to plan sponsors, including employer 
corporations, unions, managed care organizations, health 
plans, insurance carriers, third-party administrators, as well 
as local, state, and federal employee programs.
Patient selection
Patients included in the analysis were required to be   18 
years of age and continuously enrolled in a plan sponsor 
throughout the study period. Patients were newly started on 
either a CCB or a statin during the study period, and ﬁ  lled 
prescriptions for both a CCB and statin simultaneously 
or within 30 days of each other, irrespective of initiation 
sequence. Five cohorts were speciﬁ  ed depending on their 
CCB and statin therapy: 1. amlodipine/atorvastatin (single 
pill); 2. amlodipine + atorvastatin; 3. amlodipine + other 
statin (not including atorvastatin); 4. atorvastatin + other 
CCB (not including amlodipine); 5. other CCB + other statin 
(not including atorvastatin or amlodipine). The index date 
was deﬁ  ned as the ﬁ  rst amlodipine/atorvastatin prescription 
for the single-pill combination cohort. For patients taking 
CCB + statin treatments as 2 pills, the index date was the 
prescription claim ﬁ  ll date of the second medication class. 
Patients were followed for 180 days from the index date to 
calculate study outcomes. In an additional analysis, patient 
adherence at 1 year was evaluated for a subset of patients 
from the primary analysis who had at least 1 full year of 
follow-up data. Patients’ pharmacy utilization in the 180 
days prior to the index date was used to calculate baseline 
measures such as comorbidity indices.
Patient and regimen characteristics
Age and gender were collected for each patient, as well as 
several variables describing the patient’s pharmacy beneﬁ  t 
and medication-taking history, as described below. Busi-
ness type included commercial managed care organization 
(MCO), managed Medicare plans, managed Medicaid 
plans, and self-insured payers. Formulary type deﬁ  ned the 
pharmacy beneﬁ  t plan as either open formulary, where all 
medications are available under a plan sponsor’s pharmacy 
beneﬁ  t and members would pay a co-payment amount, or a 
closed formulary, where selected medications are not covered 
and patients would incur total out-of-pocket cost for these 
medications. Number of drugs used at baseline was deﬁ  ned 
by the unique number of medications utilized. Combination 
tablets including more than 1 drug were only counted as a 
single medication in this measure. Other speciﬁ  c medications 
considered at baseline were the continuing study medications 
(CCB or statin), angiotensin-converting enzyme inhibitors, 
beta-blockers, diuretics, angiotensin receptor blockers, coro-
nary vasodilators, digoxin, platelet aggregation inhibitors, 
nitrates, antidiabetic agents, and antidepressants. Adher-
ence patterns at baseline were estimated using prescription 
use prior to the index date. First DataBank (First DataBank 
Inc. 2006) classiﬁ  cation methodology was used to identify 
medications for chronic conditions. The prescription claims 
for these medications are ﬂ  agged as being either new or 
reﬁ  ll prescriptions. Using these data, a proxy measure for 
prior adherence was obtained by calculating: (number of 
reﬁ  lls)/(number of reﬁ  lls + new claims), where patients with 
a greater proportion of reﬁ  lls for chronic medications are 
deemed more compliant at baseline.
Outcomes of interest
The primary outcome of interest was adherence, measured 
using the proportion of days covered (PDC). The PDC is 
the proportion of days in the study period that the treat-
ment regimen is available to the patient, as observed from 
pharmacy claims data (Benner et al 2002; Chapman et al 
2005; Ho et al 2006). A ‘covered day’ for the purposes of 
the PDC requires the patient to have access to both drugs Vascular Health and Risk Management 2008:4(3) 675
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on a given day during the observation period (ie, for the 
2-pill treatment cohorts, a day covered on both therapies is 
required). Using this method, in scenarios where an overlap 
in medication reﬁ  lls exists, the claims and respective days 
supply were shifted forward in the corresponding amount 
of overlap. Days supply falling beyond the 180-day study 
period were truncated and not used in the PDC calculation. 
For these cohorts, the days supply associated with switching 
to a different statin or CCB medication was credited to the 
initial respective study cohorts. Patients were considered 
adherent if PDC was   80% (over 180 days for the main 
analysis, or 360 days for the 1-year analysis) (Benner et al 
2002; Chapman et al 2005; Ho et al 2006).
A secondary outcome was non-persistence or discontinu-
ation of therapy, measured as the number of days until the 
ﬁ  rst 30-day gap in therapy (Larsen et al 2002). A sensitivity 
analysis was undertaken using the medication possession 
ratio (MPR), calculated as the average of the days supplied 
with a CCB and the days supplied with a statin divided 
by the study period (patients were considered adherent if 
MPR   80%) (McCombs et al 1994; Halpern et al 2006). 
It should be noted that the deﬁ  nitions of PDC and MPR for 
the measurement of adherence with multiple drugs have not 
been ﬁ  rmly established in the literature. However, for the 
purposes of our study, MPR differed to the PDC measurement 
in that patients did not need to have access to both drugs on 
the same day to be considered adherent.
Statistical analyses
The primary end point was the adjusted likelihood of 
achieving 80% adherence with amlodipine/atorvastatin 
vs other study cohorts. The secondary end point was the 
adjusted hazard of discontinuing therapies with amlodipine/
atorvastatin vs other study cohorts.
Data extraction and statistical analyses were performed 
using SAS® software, Version 9.1.3 (SAS Institute, Inc, Cary, 
NC, USA). T-tests, F-tests, or Chi-square tests were used to 
check for differences in baseline characteristics and outcomes 
between the amlodipine/atorvastatin cohort and all other 
cohorts. Adjustments for differences as observed in Table 1 
were performed using a propensity-score weighting tech-
nique to balance treatment groups and address the potential 
for treatment selection bias due to non-random assignment 
of treatment by physicians (D’Agostino and Kwan 1995; 
Table 1 Patient baseline demographics
 Amlodipine/  Amlodipine  +   Amlodipine +   Other CCB +   Other CCB + 
 atorvastatin  atorvastatin  other  statin  atorvastatin  other  statin
Patients        
(N = 4703)  n = 795  n = 735  n = 1163  n = 652  n = 1358
Ageb, mean (SD) years  61.4 (12.0)  62.8 (12.6)  63.1 (12.1)  62.1 (11.4)  64.4 (12.3)
Femaleb, %  42.5  55.6  47.8  57.5  55.3
Drugs at baselineb, mean (SD)  6.0 (5.0)  8.1 (5.0)  8.2 (5.1)  8.2 (5.1)  8.1 (5.3)
Business typeb, %         
 Commercial  (MCO)  81.0  68.8  75.5  66.4  56.4
 Medicaid  2.4  17.1  7.9  19.2  9.7
 Medicare  0.9  1.9  3.3  2.0  18.3
 Self-insured  15.7  10.5  12.0  10.0  10.7
Number of drug classes utilizedb,c 6.6  7.4  7.6  7.6  7.5
Maintenance medication reﬁ  lla, %  57.1  60.9  62.5  60.3  59.9
Statin (CCB new start)b, %  61.3  54.5  62.9  36.5  42.3
CCB (statin new start)b, %  38.6  45.4  37.0  63.4  57.6
Medication usage, %         
 ACE  inhibitorb 36.6  46.5  43.4  41.2  42.4
 Beta-blockerb 36.8  42.8  43.5  31.7  29.3
 Diuretica  9.4 14.9  15.2 14.4 13.8
 ARBb 29.3  19.4  24.0  17.3  13.5
 Coronary  vasodilatora  8.4 12.5  12.2 11.0 9.7
 Digoxinb 1.5  2.9  4.1  5.6  5.8
  Platelet aggregation inhibitorb 11.1  10.2  10.0  9.0  5.8
 Antidiabetic  agenta 25.5  30.2  32.4  31.4  28.6
 Antidepressanta 17.2  20.5  19.3  22.3  22.3
ap   0.05; bp   0.0001 tests for differences among all cohorts.
cNumber of drugs classes utilized based on First DataBank (First DataBank Inc. 2006) therapeutic categories.
Abbreviations: ACE, angiotensin-converting enzyme;  ARB, angiotensin receptor blocker; CCB, calcium channel blocker; MCO, managed care organization.Vascular Health and Risk Management 2008:4(3) 676
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D’Agostino 1998; Hirano and Imbens 2001; D’Agostino 
and D’Agostino 2007; Schneeweiss et al 2008). Propensity 
score weighting was selected based on a recent comparative 
simulation that showed this method to be more robust at 
minimizing bias than other risk adjustment methods, even if 
the relationship between the observed outcomes and the treat-
ment assignment mechanism was misspeciﬁ  ed (Lunceford 
and Davidian 2004). To apply this method, the propensity 
score was calculated as the probability of patients receiving 
each treatment, conditional on the potential confounders 
listed in Table 1. A propensity score weight was created as 
the inverse of the propensity score. The primary outcome, 
odds ratio for achieving adherence   80%, was calculated 
using logistic regression, controlling for the 15 confound-
ers as well as weighting each observation by the propensity 
score. Therefore, the propensity score weighting addresses 
the factors associated with the treatment selection process, 
and the multivariable logistic regression model measured 
the effect of treatment on adherence while controlling for 
baseline confounders.
Adjusted results are presented as the odds ratio (OR) with 
95% conﬁ  dence intervals (CI) for the adherence outcome, 
and as the hazard ratio (HR) with 95% CI for the persistence 
outcome. In all analyses differences were considered signiﬁ  -
cant at the level of p   0.05.
Results
Study population
A total of 4703 patients met the study criteria. At baseline, 
the mean age was 63.0 years, 51.6% of patients were female, 
10.7% took nitrate/coronary vasodilators, and 29.6% took 
antidiabetic medications. The mean number of baseline 
medications was 7.8. These characteristics varied between 
the 5 cohorts; patients in the amlodipine/atorvastatin cohort 
were younger than those in the other cohorts, and more were 
male. The amlodipine/atorvastatin cohort also appeared to 
be healthier than other cohorts, utilizing fewer drugs at base-
line, eg, a lower proportion received angiotensin-converting 
enzyme inhibitors, diuretics, coronary vasodilators, digoxin, 
antidiabetic agents, and antidepressants (Table 1). The 
majority of all patients were enrolled in an MCO (56.4%–
81.0%). Patients in the other CCB + atorvastatin cohort, and 
those in the amlodipine + atorvastatin cohort were slightly 
more likely to be Medicaid enrollees, while those patients 
in the other CCB + other statin cohort were more likely 
to be Medicare enrollees. Patients receiving amlodipine/
atorvastatin were more likely to be enrolled in a self-insured 
employer population.
Unadjusted mean adherence levels
Pair-wise comparisons of unadjusted mean adherence 
levels showed signiﬁ  cant differences between single-pill 
amlodipine/atorvastatin and all other cohorts. Adherence for 
amlodipine/atorvastatin patients was on average 9%–17% 
higher compared with the other cohorts (Figure 1A). The 
proportion of patients achieving adherence (PDC   80%) 
was higher in the amlodipine/atorvastatin cohort than in the 
other 4 cohorts (Figure 1B).
Adjusted proportion of patients achieving 
adherence
Adjustments were made for baseline cohort differences 
using the propensity score weighting models to account for 
potential treatment selection bias at baseline. Chi-square 
and ANOVA tests conﬁ  rmed that the differences between 
cohorts on the 15 variables were not signiﬁ  cantly different 
following adjustment. After adjustments at 180 days fol-
low-up, patients taking single-pill amlodipine/atorvastatin 
Figure 1 (A) Unadjusted mean PDC, and (B) percentage of patients achieving the 
primary adherence endpoint (PDC   80%) at 180 days’ follow-up.
*p   0.0001 amlodipine/atorvastatin vs all other cohorts.
Abbreviations: CCB, calcium channel blocker; PDC, proportion of days covered.
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were approximately twice as likely to be adherent as patients 
taking amlodipine + atorvastatin separately (OR, 1.95; 95% 
CI, 1.80–2.13, p   0.0001; Figure 2). Additionally, patients 
taking amlodipine/atorvastatin were between 2.06 and 3.10 
times more likely to be adherent than patients taking any 
of the other 3 drug treatment regimens (amlodipine + other 
statin, other CCB + atorvastatin, and other CCB + other statin; 
p   0.0001; Figure 2).
Non-persistence/therapy discontinuation
At 180 days, 71% of single-pill amlodipine/atorvastatin 
patients remained on therapy in comparison with 61% of 
patients receiving amlodipine and atorvastatin as separate pills 
and 50%–59% of patients receiving the other treatment com-
binations (Figure 3A). After adjusting for covariates, patients 
taking amlodipine/atorvastatin were 19% less likely to dis-
continue therapy than those taking atorvastatin + amlodipine 
separately (HR, 0.81; 95% CI, 0.75–0.87, p   0.0001). 
Patients in the other 2-pill regimen cohorts were between 22% 
and 35% more likely to discontinue therapy compared with 
the amlodipine/atorvastatin cohort (Figure 3B).
Patient adherence after 1 year of therapy
In a subset analysis, patient adherence was evaluated over 
1 year among patients who were enrolled for an additional 
6 months’ follow-up (N = 3561; 24% drop in patient count 
from the original cohort). The baseline characteristics 
for this subset of patients were comparable to the overall 
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Amlodipine/atorvastatin vs amlodipine + atorvastatin
Amlodipine/atorvastatin vs amlodipine + other statin
Amlodipine/atorvastatin vs other CCB + atorvastatin
Amlodipine/atorvastatin vs other CCB + other statin
Multivariate odds ratio of achieving PDC ≥ 80% (95% CI)
Amlodipine/atorvastatin
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Amlodipine/atorvastatin
more likely to achieve adherence
1.95 (1.80-2.13)*
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2.85 (2.61-3.10)*
Figure 2 Adjusted probability of achieving adherence (PDC   80%) at 180 days’ follow-up. Logistic regression model analysis adjusting for covariates including age, gender, 
business type, formulary type, baseline antihypertensive therapy, cardiovascular disease medications, antidiabetic medications, antidepressants, number of drugs, co-payments, 
and maintenance medication reﬁ  ll percentage.
*p   0.0001 for group comparison parameter estimate in the regression.
Abbreviations: CCB, calcium channel blocker; PDC, proportion of days covered.
patient population. At 1 year, in the single-pill amlodipine/
atorvastatin cohort, 63.9% of patients achieved adherence. 
In comparison, the proportion of patients on a 2-pill 
regimen who were adherent with both antihypertensive 
and lipid-lowering medications ranged from 33.1% to 
43.6%. After adjusting for cohort differences at baseline 
for this 1-year subgroup, patients given single-pill amlo-
dipine/atorvastatin were found to be approximately 3-times 
more likely to achieve adherence over 1 year of follow-up 
(Figure 4).
Sensitivity analysis
In order to determine the effect of the method of measuring 
adherence used on the observed differences in adherence 
between patients receiving single-pill amlodipine/atorvas-
tatin and the other treatment cohorts, we conducted a sensitiv-
ity analysis for which we used MPR in place of PDC as the 
measurement of adherence. This analysis found a consistent 
trend for greater adherence with amlodipine/atorvastatin vs 
2-pill CCB + statin regimens at both 6 months (adjusted ORs, 
1.19–1.82, p   0.0001) and 1 year (adjusted ORs, 1.59–1.92, 
p   0.0001). However, the magnitude of the adherence ben-
eﬁ  t was smaller here than with the PDC measurement.
Discussion
This adherence study demonstrated that patients taking 
single-pill combination amlodipine/atorvastatin were more 
likely to be adherent and persistent with therapy compared Vascular Health and Risk Management 2008:4(3) 678
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Figure 3 (A) Estimated unadjusted Kaplan-Meier curves for time to therapy discontinuation, and (B) adjusted hazard ratio of discontinuing therapies. Proportional hazard 
model analysis adjusting for covariates including age, gender, business type, formulary type, baseline antihypertensive therapy, cardiovascular disease medications, antidiabetic 
medications, antidepressants, number of drugs, co-payments, and maintenance medication reﬁ  ll percentage.
*p   0.0001 for group comparison parameter estimate in the regression.
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with patients taking CCBs and statins as 2 separate pills, over 
both 6 months and 1 year.
The probability of achieving adherence using single-pill 
amlodipine/atorvastatin was 1.95-times greater than with the 
parent compounds amlodipine and atorvastatin administered 
separately (p   0.0001), and ranged from 2.06- to 3.10-times 
greater than for any of the other CCB and statin regimens 
studied (p   0.0001). For the additional 1-year analysis, 
patients receiving amlodipine/atorvastatin were 2.41- to 
3.50-times more likely to achieve adherence than patients on 
a 2-pill CCB and statin regimen. For the comparison of each 
of the 2-pill regimen cohorts with amlodipine/atorvastatin, 
the magnitude of the adherence difference was greater after 
1-year follow-up (for those patients remaining on therapy 
over this time) than at 6 months. Furthermore, patients tak-
ing single-pill amlodipine/atorvastatin were less likely to 
discontinue therapies compared with those taking the parent 
compounds or other CCB and statin combinations.
The adherence beneﬁ  t of single-pill amlodipine/atorv-
astatin may at least in part be due to the reduction in pill 
burden, and the synchronization of therapy initiation, given 
that previous observations have shown these factors to 
increase patient adherence to multiple therapies (Dezii 2000; 
Vanderpoel et al 2004; Chapman et al 2005; Gerbino and 
Shoheiber 2007).
In order to achieve maximum beneﬁ  ts in terms of clinical 
outcomes, it is important that clinicians consider patients’ 
global cardiovascular risk, and address the management 
of all coexisting cardiovascular risk factors (Expert Panel 
on Detection, Evaluation, and Treatment of High Blood 
Cholesterol in Adults 2001; Sever et al 2003; Lopez et al 
2007). This is reﬂ  ected in current guidelines and recommen-
dations aimed at reducing the risk of cardiovascular disease 
in the population (Expert Panel on Detection, Evaluation, 
and Treatment of High Blood Cholesterol in Adults 2001). 
In particular, the use of both antihypertensive and statin 
therapies for the management of concomitant hypertension 
and dyslipidemia, or hypertension in the presence of mul-
tiple cardiovascular risk factors, is recognized as providing 
signiﬁ  cant beneﬁ  ts for lowering the risk of cardiovascular 
events (Heart Protection Study Collaborative Group 2002; 
Sever et al 2003). However, lack of patient adherence to 
multiple therapies compromises this treatment strategy and 
is associated with poor clinical outcomes (Benner et al 2002; 
Wei et al 2002; Blackburn et al 2005; Chapman et al 2005; 
Sokol et al 2005; Bramley et al 2006; Burnier 2006; Ho 
et al 2006; Kulkarni et al 2006). As a result, concerns that 
increasing a patient’s pill burden will decrease adherence 
may discourage physicians from adding further medications 
to a patient’s existing regimen, despite potential therapeutic 
beneﬁ  ts. The combination of amlodipine and atorvastatin in 
a single pill may help to allay such concerns with regard to 
the addition of statin therapy in hypertensive patients with 
high cardiovascular risk, or an antihypertensive in those with 
elevated blood pressure who are already receiving a statin. 
In support of this, the present study provides preliminary 
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Figure 4 Adjusted probability of achieving adherence (PDC   80%), over 1-year follow-up. Logistic regression model analysis adjusting for covariates including age, gender, 
business type, formulary type, baseline antihypertensive therapy, cardiovascular disease medications, antidiabetic medications, antidepressants, number of drugs, co-payments, 
and maintenance medication reﬁ  ll percentage.
*p   0.0001 for group comparison parameter estimate in the regression.
Abbreviations: CCB, calcium channel blocker; PDC, proportion of days covered.Vascular Health and Risk Management 2008:4(3) 680
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indications that single-pill amlodipine/atorvastatin may help 
address issues of poor adherence to antihypertensive and 
lipid-lowering medications. Additional studies assessing 
whether increased adherence and persistence with single-pill 
amlodipine/atorvastatin translates to improved attainment 
of blood pressure and lipid goals and, more importantly, a 
reduced incidence of cardiovascular events and improved 
health outcomes for the patient, are warranted.
The study limitations include the potential for bias 
that may have occurred due to the retrospective and non-
randomized nature of the design, and that possible drug 
treatment selection bias may not be fully taken into account 
by the propensity weighting methodology used. However, 
Chi-square and ANOVA tests of differences between cohorts 
on the 15 independent variables used for adjustment found 
no signiﬁ  cant differences after adjustment methods were 
applied. Indications for single-pill amlodipine/atorvastatin 
may include an expected lack of adherence to medica-
tions, which may be a confounding factor in this analysis, 
although previous adherence patterns were included as a 
covariate for propensity score weight. In addition, while 
patients in the single-pill cohort were younger, took fewer 
baseline medications, and were more likely to be enrolled 
in an MCO than in the other cohorts (characteristics which 
could potentially inﬂ  uence the likelihood of being adher-
ent) these factors were also adjusted for in the proportional 
hazards analysis. Limited variables were available due to 
the lack of data related to medical diagnoses and severity 
of illness.
Other important confounding factors that could not be 
considered in this administrative claims analysis are the 
quality of care, intensity of counseling, patient’s perception 
and beliefs towards the effectiveness of treatment (ie, poten-
tial for self-efﬁ  cacy), the health care resources available, 
and the effect on clinical end points (eg, blood pressure and 
cholesterol). However, this study was speciﬁ  cally designed 
to assess differences in observed adherence between treat-
ment regimens in a real-world setting, and was not intended 
to assess the inﬂ  uence of these other factors.
Assessing adherence based on prescription reﬁ  ll rates is 
a proxy measure only and a patient’s true pattern of medi-
cation taking may still be unknown. In addition, the timing 
of prescription reﬁ  ll patterns was assumed to correlate with 
medication consumption, which may amplify the magnitude 
of adherence differences observed using PDC vs MPR. 
However, it has been noted that most studies of the valid-
ity of prescription reﬁ  ll rates have shown that measures of 
prescription reﬁ  ll rates are signiﬁ  cantly associated with other 
measures of adherence, serum drug levels, or physiologic 
drug effects (Steiner and Prochazka 1997). The observed 
beneﬁ  ts on adherence of single-pill amlodipine/atorvastatin 
compared with 2-pill CCB and statin regimens were 
consistent with the sensitivity analysis using the MPR as an 
alternative method of measuring adherence, although the 
magnitude of the difference was lower.
Despite the limitations detailed above, the beneﬁ  ts on 
adherence of single-pill amlodipine/atorvastatin compared 
with a 2-pill CCB and statin regimen were robust in that 
they were observed using 2 methods of measurement 
(PDC and MPR), at 2 points in time, and are consistent 
with the evaluation of persistence. Given the high level 
of signiﬁ  cance observed in these comparisons, additional 
statistical adjustments for multiple comparisons were not 
necessary as they would have remained signiﬁ  cant under 
such adjustments.
Following the ﬁ  ndings from this study, physicians who 
prescribe antihypertensive and lipid-lowering therapies for 
the management of cardiovascular risk should consider the 
potential beneﬁ  ts of therapy adherence that may be afforded 
by a single-pill, such as amlodipine/atorvastatin, as a means 
of simplifying their patient’s treatment regimen, reducing 
pill burden, and synchronizing antihypertensive and statin 
therapy (Bangalore et al 2007). Single-pill amlodipine/ator-
vastatin therapy provides a potential opportunity for improv-
ing adherence over a multi-pill treatment regimen, although 
further studies are required to determine whether this will 
result in improvements in therapeutic goal attainment and 
patients’ long-term clinical outcomes, and in lower health-
service utilizations.
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